Centre for Addiction and Mental Health, Canada.
J Psychiatr Res. 2012 Jan;46(1):1-11. doi: 10.1016/j.jpsychires.2011.09.022. Epub 2011 Oct 26.
Brain derived neurotrophic factor (BDNF) has been associated with the pathophysiology of schizophrenia (SCZ). However, it remains unclear whether alterations in BDNF observed in patients with SCZ are a core part of disease neurobiology or a consequence of treatment. In this manuscript we review existing knowledge relating the function of BDNF to synaptic transmission and neural plasticity and the relationship between BDNF and both pharmacological and non-pharmacological treatments for SCZ. With regards to synaptic transmission, exposure to BDNF or lack of this neurotrophin results in alteration to both excitatory and inhibitory synapses. Many authors have also evaluated the effects of both pharmacological and non-pharmacological treatments for SCZ in BDNF and despite some controversial results, it seems that medicated and non-medicated patients present with lower levels of BDNF when compared to controls. Further data suggests that typical antipsychotics may decrease BDNF expression whereas mixed results have been obtained with atypical antipsychotics. The authors found few studies reporting changes in BDNF after non-pharmacological treatments for SCZ, so the existing evidence in this area is limited. Although the study of BDNF provides some new insights into understanding of the pathophysiology and treatment of SCZ, additional work in this area is needed.
脑源性神经营养因子（BDNF）与精神分裂症（SCZ）的病理生理学有关。然而，BDNF 在 SCZ 患者中的改变是疾病神经生物学的核心部分还是治疗的结果仍不清楚。在本文中，我们回顾了与 BDNF 功能与突触传递和神经可塑性之间的关系，以及 BDNF 与 SCZ 的药物和非药物治疗之间的关系。关于突触传递，BDNF 的暴露或缺乏会导致兴奋性和抑制性突触发生改变。许多作者还评估了 SCZ 的药物和非药物治疗对 BDNF 的影响，尽管存在一些有争议的结果，但与对照组相比，接受药物和非药物治疗的患者的 BDNF 水平似乎较低。进一步的数据表明，典型的抗精神病药可能会降低 BDNF 的表达，而使用非典型抗精神病药则得到了不同的结果。作者发现很少有研究报告 SCZ 的非药物治疗后 BDNF 的变化，因此该领域的现有证据有限。尽管 BDNF 的研究为理解 SCZ 的病理生理学和治疗提供了一些新的见解，但该领域还需要进一步的研究。
